19.04.2018 • NewsDSM DyneemaElaine Burridge

DSM Dyneema Ends Patent Dispute with FMS

DSM Dyneema Ends Patent Dispute with FMS
DSM Dyneema Ends Patent Dispute with FMS

DSM Dyneema has concluded a dispute with Israeli firm FMS Enterprises Migun (FMS) relating to the infringement and validity of the Dutch company’s patents for ultra-high molecular weight polyethylene (UHMWPE).

Details of the agreement were not disclosed

This is the final step in a series of disputes between the two, including earlier unsuccessful attempts by FMS to challenge the validity of DSM Dyneema’s patent on an improved UHMWPE.

The latest action by DSM Dyneema against FMS was filed in November 2017 and was concluded in March this year.

“We are very pleased with this outcome, which again confirms the quality of our patents,” said Olivier Janin, vice president, marketing and sales at DSM Dyneema, adding that the company has consistently and vigorously defended its intellectual property on many occasions and will continue to do so.

DSM Dyneema has also ended another dispute with FMS relating to a patent concerning improved unidirectional sheets and pressed protective life saving articles made of such sheets, including inserts, helmets and vehicle panels. FMS had opposed DSM Dyneema’s patent, which was eventually granted on Mar. 22, 2018.

 

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.